Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 6,702 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,702 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $146.03, for a total value of $978,693.06. Following the transaction, the chief executive officer now directly owns 203,354 shares of the company’s stock, valued at $29,695,784.62. The trade was a 3.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41.

Natera Price Performance

Shares of NTRA stock opened at $150.87 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The firm has a market cap of $20.40 billion, a P/E ratio of -85.72 and a beta of 1.80. The business’s 50 day moving average price is $162.25 and its 200-day moving average price is $149.27.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research note on Friday, February 28th. Robert W. Baird boosted their target price on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. increased their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Guggenheim boosted their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Finally, StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of NTRA. LRI Investments LLC bought a new stake in Natera during the 4th quarter valued at approximately $29,000. Blue Trust Inc. raised its position in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Finally, Principal Securities Inc. grew its stake in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.